瑞舒伐他汀对冠心病患者的疗效及IL-35、NF-κB水平的影响

Therapeutic effect and influence of rosuvastatin on IL-35 and NF-κB levels in patients with coronary heart disease

目的:观察瑞舒伐他汀对冠心病患者的临床疗效及白介素-35(IL-35)、核因子-κB(NF-κB)水平的影响。方法:85例冠心病患者被随机分为瑞舒伐他汀组(43例,在常规治疗基础上接受瑞舒伐他汀钙治疗)和阿托伐他汀组(42例,在常规治疗基础上接受阿托伐他汀钙治疗),疗程均为8周。测量比较两组患者治疗前后的心功能指标[心脏指数(CI),心排血量(CO),左室射血分数(LVEF)和左室舒张末期内径(LVEDd)],治疗总有效率以及血清IL-35和NF-κB水平。结果:与治疗前比较,治疗后两组的CI、CO、LVEF和IL-35水平显著升高,LVEDd和NF-κB水平显著降低(P<0.05或<0.01)。与阿托伐他汀组比较,瑞舒伐他汀组治疗后CI[(3.54±0.72)L·min-1·m-2比(3.88±0.83)L·min-1·m-2],CO[(3.78±0.89)L/min比(4.94±0.96)L/min],LVEF[(56.20±9.71)%比(63.48±14.15)%]和血清IL-35[(96.26±24.33)pg/ml比(106.92±27.26)pg/ml]水平升高更显著,LVEDd[(4.71±0.89)cm比(4.36±0.75)cm]和NF-κB[(21.51±5.01)ng/ml比(18.32±5.17)ng/ml]水平降低更显著,P均<0.05。瑞舒伐他汀组临床总有效率(95.35%比76.19%)显著高于阿托伐他汀组,P<0.05。结论:瑞舒伐他汀治疗冠心病疗效较阿托伐他汀显著,其降脂外的心脏保护作用可能与调节血中炎症因子白介素-35、核因子-κB水平有关。

Objective：To observe therapeutic effect and influence of rosuvastatin on levels of interleukin（IL）-35 and nuclear factor-κB（NF-κB）in patients with coronary heart disease（CHD）.Methods：A total of 85 CHD patients were randomly divided into rosuvastatin group（n=43,received rosuvastatin calcium therapy based on routine treatment）and atorvastatin group（n=42,received atorvastatin calcium therapy based on routine treatment）,both groups were treated for eight weeks all.Cardiac index（CI）,cardiac output（CO）,left ventricular ejection fraction（LVEF）,left ventricular enddiastolic dimension（LVEDd）,serum levels of IL-35 and NF-κB,and total effective rate were measured and compared between two groups before and after treatment.Results：Compared with before treatment,there were significant rise in CI,CO,LVEF and IL-35 level,and significant reductions in LVEDd and NF-κB level in both groups after treatment（P〈0.05or0.01）.Compared with atorvastatin group after treatment,there were significant rise in CI [（3.54±0.72）L·min^-1·m^-2vs.（3.88±0.83）L·min^-1·m^-2,CO [（3.78±0.89）L/min vs.（4.94±0.96）L/min],LVEF [（56.20±9.71）% vs.（63.48±14.15）%]and serum IL-35level[（96.26±24.33）pg/ml vs.（106.92±27.26）pg/ml],and significant reductions in LVEDd[（4.71±0.89）cm vs.（4.36±0.75）cm]and NF-κB level[（21.51±5.01）ng/ml vs.（18.32±5.17）ng/ml]in rosuvastatin group,P〈0.05 all.Total effective rate of rosuvastatin group（95.35% vs.76.19%）was significantly higher than that of atorvastatin group,P〈0.05.Conclusion：Rosuvastatin possesses more significant therapeutic effect than that of atorvastatin on coronary heart disease,and its heart protection effect besides lipid lowering may be related to regulating levels of interleukin-35 and nuclear factor-κB.